$35M Teva QVAR Inhaler Antitrust Class Action Settlement

Teva Pharmaceuticals has agreed to pay $35 million to settle a class action alleging it blocked generic versions of the QVAR asthma inhaler from reaching the market for nearly a decade. If you purchased QVAR inhalers or paid for them through insurance between 2012 and 2020, you may be entitled to a cash pro rata payment.

Do I Qualify?

You may be eligible if:

• Anyone who purchased QVAR inhalers or paid for them through insurance between 2012 and 2020
• Purchase records or insurance documentation are recommended to support your claim
• You submit a valid claim before August 11, 2026

Proof is recommended. Purchase records or insurance documentation showing QVAR purchases during the qualifying period will help maximize your payment.

What Happened?

Teva Pharmaceuticals, one of the world's largest generic drug manufacturers, was sued for allegedly blocking generic versions of the QVAR asthma inhaler from reaching the market for nearly a decade. The lawsuit alleged that Teva used a combination of legal tactics and agreements with competitors to delay generic competition, allowing it to maintain artificially high prices for the brand-name inhaler.

This type of anticompetitive behavior — sometimes called "pay for delay" — has been the target of FTC enforcement actions and private litigation for years. By keeping cheaper generics off the market, Teva allegedly overcharged consumers and health insurance plans billions of dollars over the affected period. Teva agreed to pay $35 million to settle the class action.

How Much Will I Actually Get?

The pro rata payment from the $35 million fund depends on how many valid claims are filed and the amount each claimant paid for QVAR during the qualifying period. Claimants with insurance records showing QVAR purchases will receive higher payments. Deadline is August 11, 2026.

Last updated: June 15, 2026 | Information verified from court records and official settlement documents.

Frequently Asked Questions